What is Dynavax Technologies 12-1 Month Momentum %?
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-04), Dynavax Technologies's 12-1 Month Momentum % is 10.62%.
The industry rank for Dynavax Technologies's 12-1 Month Momentum % or its related term are showing as below:
DVAX's 12-1 Month Momentum % is ranked better than 65.41% of 1116
companies
in the Drug Manufacturers industry
Industry Median: -6.64
vs DVAX: 10.62
Competitive Comparison of Dynavax Technologies's 12-1 Month Momentum %
For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavax Technologies's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Dynavax Technologies's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Dynavax Technologies 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Dynavax Technologies's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Dynavax Technologies (Dynavax Technologies) Business Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DVAX has been successfully added to your